[PDF] psu.edu

[PDF][PDF] Older age may associate with better therapeutic effect of gefitinib in non-small cell lung cancer

GC Chang, YTY CK, SH Lin - J Chin Oncol Soc, 2008 - Citeseer
… Efficacy of gefitinib, aninhibitor of the epidermal growth factor receptor tyrosine kinase, in …
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and fu- …
被引用次数：2 相关文章
[PDF] hanspub.org

[PDF][PDF] Research progress of TCM combined with EGFR-TKI drugs in the treatment of advanced non-small cell lung cancer

WT Guo, WZ Shou - Adv Clin Exp Med, 2020 - pdf.hanspub.org
… 本文将对皮细胞生长因子受体(epidermal growth factor receptor, EGFR)酪氨酸激酶抑制剂(tyrosine
kinase inhibitor, TKI)类药物的研究进展,中医药联 合靶向治疗的临床研究进行综合阐述,为…
被引用次数：1 相关文章

Gefitinib plus Fuzheng Kang'ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a …

X Yang, X Chai, W Wu, S Long, H Deng, Z Pan… - Chinese journal of …, 2018 - Springer
… Gefitinib is an oral EGFR tyrosine kinase inhibitor (EGFR-TKI). In two large multicenter,
randomized phase Ⅱ studies, the response rate was 9% to 19.0%, and gefitinib was well …
被引用次数：21 相关文章 所有 7 个版本

在Ⅰ 期和Ⅱ 期临床试验中, 使用表皮生长因子受体酪氨酸激酶抑制剂——吉非替尼(易瑞沙, ZD1839) 治疗实体肿瘤患者后其眼部的表现

王海燕 - 世界核心医学期刊文摘: 眼科学分册, 2005 - cqvip.com
… agent gefitinib (“ Iressa” , ZD1839), an epidermal growth factor receptor tyrosine kinase
inhibitor… for 221 patients in Phase I trials of gefitinib and 425 patients in Phase II trials revealed no …
相关文章 所有 2 个版本

[引用][C] Revisiting squamous cell carcinoma of the lungs–a disease given less attention

YM Chen, JF Shih, CM Tsaim, YC Lee, RP Perng… - J Chin Oncol Soc, 2009
被引用次数：3 相关文章

[引用][C] The value analysis of blood brain barrier permeability in the treatment of multiple brain metastases patients with non-small cell lung cancer

Z Yongli, D Jigang, L Bo, L Maojiang, C Yan… - J. Mod. Oncol, 2017
被引用次数：1 相关文章

[引用][C] Efficacy of gefitinib, erlotinib and icotinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation

RN Cong, F Gu, B Wang - J Mod Oncol, 2018
被引用次数：1 相关文章

製備DUSP13 抗體以探討具獲得性Gefitinib 抗藥性之肺腺癌

王筱珺 - 2014 - tdr.lib.ntu.edu.tw
… 生長因子受體(epidermal growth factor receptor, EGFR)突變的… 胺酸激酶抑制劑-吉非替尼
(Gefitinib),儘管此抑制劑具有顯著的治療效果… Gefitinib is an EGFR-tyrosine kinase inhibitor that has …
相关文章
[HTML] nih.gov

[HTML][HTML] EGFR 基因突变状态未知NSCLC 治疗——TKI 还是化疗？

刘晓晴， 许晶 - Chinese Journal of Lung Cancer, 2014 - ncbi.nlm.nih.gov
… (NSCLC) with clear epidermal growth factor receptor (EGFR) … to epidermal growth factor
receptor-tyrosine kinase inhibitors (… : a phase Ⅱ trial comparing pemetrexed with gefitinib as …
被引用次数：2 相关文章 所有 5 个版本
[PDF] jebm.cn

表皮生长因子受体酪氨酸激酶抑制剂在野生型进展期非小细胞肺癌治疗中的地位

辛田， 马锐 - 循证医学, 2014 - jebm.cn
… Multi-institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients …
epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study [J]…
相关文章 所有 3 个版本